…
America Great Health operates as a biotechnology company in the United States. The company focuses on the research and development of protein and peptide small molecular drugs; and manufacture and sale of AI cloud computing-based diagnostic and medical devices, cell therapy, and re-generational medicine and supplements. The company was formerly known as Crown Marketing and changed its name to America Great Health in March 2017. America Great Health is based in Alhambra, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -0.72M | -1.23M | -0.78M | -0.78M | -0.27M |
| Minority interest | - | 0.00M | 0.01M | 0.02M | 0.06M |
| Net income | -0.72M | -1.22M | -0.76M | -0.76M | -0.27M |
| Selling general administrative | 0.67M | 0.86M | 0.66M | 0.66M | 0.29M |
| Selling and marketing expenses | 0.05M | 0.10M | 0.00M | 0.00M | 0.09M |
| Gross profit | 0.34M | 0.17M | 0.17M | 0.17M | 0.05M |
| Reconciled depreciation | - | 0.01M | 0.01M | 0.01M | 0.01M |
| Ebit | -0.40M | -0.78M | -0.46M | -0.46M | -0.24M |
| Ebitda | -0.38M | -0.77M | -0.45M | -0.45M | -0.25M |
| Depreciation and amortization | 0.01M | 0.01M | 0.01M | 0.01M | -0.01M |
| Operating income | -0.38M | -0.78M | -0.49M | -0.49M | -0.24M |
| Other operating expenses | 0.77M | 1.08M | 0.70M | 0.70M | 0.44M |
| Interest expense | 0.34M | 0.44M | 0.32M | 0.32M | 0.02M |
| Interest income | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | - | -0.34M | -0.44M | -0.32M | -0.19M |
| Income tax expense | - | - | 0.34M | 0.34M | 0.02M |
| Total revenue | 0.39M | 0.29M | 0.20M | 0.20M | 0.20M |
| Total operating expenses | 0.72M | 0.95M | 0.66M | 0.66M | 0.29M |
| Cost of revenue | 0.05M | 0.12M | 0.04M | 0.04M | 0.14M |
| Total other income expense net | -0.34M | -0.44M | -0.28M | 0.03M | -0.03M |
| Net income from continuing ops | - | -0.72M | -1.23M | -0.78M | -4.92M |
| Net income applicable to common shares | - | - | - | -0.76M | -4.87M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 0.30M | 0.32M | 0.30M | 0.30M | 0.62M |
| Other current assets | 0.03M | 0.03M | 0.02M | 0.02M | 0.02M |
| Total liab | 6.05M | 5.64M | 4.82M | 4.82M | 1.09M |
| Total stockholder equity | -5.74M | -5.23M | -4.53M | -4.45M | -0.47M |
| Other current liab | 4.39M | 1.47M | 0.67M | 0.67M | 0.32M |
| Capital stock | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -10.78M | -10.25M | -9.18M | -9.18M | -3.56M |
| Other liab | - | - | - | 0.61M | 0.38M |
| Other assets | - | - | - | 0.02M | 0.02M |
| Cash | 0.04M | 0.05M | 0.05M | 0.05M | 0.40M |
| Total current liabilities | 3.82M | 3.59M | 3.09M | 3.09M | 0.43M |
| Current deferred revenue | 0.08M | 0.06M | 0.22M | 0.22M | 0.16M |
| Net debt | 2.80M | 2.43M | 1.82M | 1.82M | 0.31M |
| Short term debt | 0.65M | 0.63M | 0.75M | 0.75M | 0.05M |
| Short long term debt | - | 0.60M | 0.61M | 0.71M | 0.18M |
| Short long term debt total | 2.84M | 2.48M | 1.87M | 1.87M | 0.71M |
| Other stockholder equity | 10.16M | 5.02M | 4.73M | 4.73M | 3.09M |
| Property plant equipment | - | - | - | 0.10M | 0.12M |
| Total current assets | 0.24M | 0.23M | 0.18M | 0.18M | 0.48M |
| Net tangible assets | - | - | - | -4.45M | -3.80M |
| Net receivables | - | 0.06M | 0.06M | 0.00M | 0.06M |
| Long term debt | - | 2.22M | 1.83M | 1.12M | 1.03M |
| Inventory | 0.16M | 0.08M | 0.11M | 0.11M | 0.01M |
| Accounts payable | 1.49M | 1.44M | 1.45M | 1.45M | 0.06M |
| Accumulated other comprehensive income | -0.00M | -0.00M | -0.00M | -0.00M | 0.00M |
| Non currrent assets other | 0.01M | 0.01M | 0.01M | 0.02M | 0.02M |
| Non current assets total | 0.07M | 0.10M | 0.12M | 0.12M | 0.14M |
| Capital lease obligations | - | 0.03M | 0.04M | 0.04M | 0.09M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | - | 0.00M | -0.04M | -0.02M |
| Change to liabilities | - | - | - | 0.08M | 1.54M |
| Total cashflows from investing activities | - | - | -0.04M | -0.04M | -0.02M |
| Net borrowings | - | 0.14M | -0.11M | 0.70M | 1.07M |
| Total cash from financing activities | 0.32M | 0.62M | 0.79M | 0.79M | 0.74M |
| Change to operating activities | - | - | - | -0.09M | 0.51M |
| Net income | -0.72M | -1.23M | -0.76M | -0.78M | -0.27M |
| Change in cash | -0.01M | 0.00M | -0.01M | -0.01M | 0.40M |
| Begin period cash flow | 0.05M | 0.05M | 0.06M | 0.06M | 0.00M |
| End period cash flow | 0.04M | 0.05M | 0.05M | 0.05M | 0.40M |
| Total cash from operating activities | -0.33M | -0.62M | -0.75M | -0.75M | -0.33M |
| Issuance of capital stock | - | 0.10M | 0.12M | 0.09M | 0.10M |
| Depreciation | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M |
| Dividends paid | - | 0.00M | 0.00M | - | - |
| Change to inventory | -0.08M | 0.02M | 0.01M | 0.01M | -0.01M |
| Change to account receivables | 0.06M | -0.06M | 0.00M | 0.00M | -0.00M |
| Other cashflows from financing activities | 0.32M | 0.62M | -0.15M | 0.70M | 0.74M |
| Change to netincome | - | - | - | -0.01M | 1.31M |
| Capital expenditures | 0.00M | 0.00M | 0.04M | 0.04M | 0.01M |
| Change in working capital | 0.46M | 0.50M | -0.09M | -0.01M | -0.08M |
| Stock based compensation | - | 0.12M | 0.07M | 0.00M | 0.00M |
| Other non cash items | 0.37M | -0.02M | -0.06M | 0.02M | 0.01M |
| Free cash flow | -0.33M | -0.62M | -0.80M | -0.80M | -0.34M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AAGH America Great Health |
- -% |
0.00 | - | - | 11.64 | 358698.71 | 20.16 | 7.21 |
| NVO Novo Nordisk A/S |
-1.06 2.73% |
37.81 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-5.64 1.08% |
515.02 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
- -% |
920.69 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
America Great Health operates as a biotechnology company in the United States. The company focuses on the research and development of protein and peptide small molecular drugs; and manufacture and sale of AI cloud computing-based diagnostic and medical devices, cell therapy, and re-generational medicine and supplements. The company was formerly known as Crown Marketing and changed its name to America Great Health in March 2017. America Great Health is based in Alhambra, California.
| Name | Title | Year Born |
|---|---|---|
| Mr. Mike Qingkun Wang | CEO, Pres, CFO, Sec. & Chairman | 1955 |
| Mr. Qinghua Chen CPA, CPA | Chief Financial Officer | 1963 |
| Mr. David Liu | Chief Operating Officer | NA |
| David Tsai | Chief Scientist | NA |
| Mr. Mike Qingkun Wang | CEO, President, CFO, Secretary & Chairman of the Board | 1955 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.